Department of Biopharmaceutics, Meiji Pharmaceutical University, Noshio 2-522-1, Kiyose, Tokyo, 204-8588, Japan.
Department of Pharmacometrics & Pharmacokinetics, Meiji Pharmaceutical University, Noshio 2-522-1, Kiyose, Tokyo, 204-8588, Japan.
Pharmacogenomics. 2020 Aug;21(12):853-862. doi: 10.2217/pgs-2020-0036. Epub 2020 Jul 23.
To predict the impact of the different and genotypes on warfarin-sorafenib interactions in whites and Asians. The influences of the and genotypes on increases in anticoagulation responses (international normalized ratio [INR]) in the presence of sorafenib were predicted using the population pharmacokinetic/pharmacodynamic (PK/PD) model in whites and Asians. INRs were predicted to be 2.0-2.1- versus 1.8-1.9-times higher in the presence of sorafenib in the ( vs ) groups than those for warfarin alone in both whites and Asians. INRs were also predicted to be 2.1-2.2- versus 1.9-2.1-times higher in the (GG or GA vs AA) groups. Warfarin-sorafenib interactions might be similar irrespective of and genotypes or ethnicity.
预测不同 CYP2C9 和 VKORC1 基因型对白人及亚洲人群华法林-索拉非尼相互作用的影响。应用群体药代动力学/药效学（PK/PD）模型预测 CYP2C9 和 VKORC1 基因型对索拉非尼存在时抗凝反应（国际标准化比值 [INR]）增加的影响。与单独使用华法林相比，在白人及亚洲人中，索拉非尼存在时，CYP2C9 （ vs ）组的 INR 预计会高出 2.0-2.1-倍至 1.8-1.9-倍，而 CYP2C9 （ GG 或 GA 与 AA ）组的 INR 预计会高出 2.1-2.2-倍至 1.9-2.1-倍。华法林-索拉非尼相互作用可能与 CYP2C9 和 VKORC1 基因型或种族无关。
